Adaptive Biotechnologies Corp
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
13. Segment Information
There areno inter-segment revenues. See Note 3, Revenuefor more information about each segment’s revenue. Our chief operating decision maker (“CODM”) is not regularly provided and does not review assets to assess each segment’s performance, make strategic decisions or allocate resources. As such, assets for reportable segments are not disclosed.
The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the three months ended March 31, 2026 and 2025 (in thousands):
| Three Months Ended March 31, 2026 · Three Months Ended March 31, 2025 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRD · Immune Medicine · Total · MRD · Immune Medicine(1) · Total | ||||||||||||
| Revenue | $67,093 | $3,781 | $70,874 | $43,721 | $8,722 | $52,443 | ||||||
| Less: | ||||||||||||
| Cost of revenue | 17,244 | * | 17,244 | 15,885 | * | 15,885 | ||||||
| Research and development | 9,226 | 13,934 | 23,160 | 9,159 | 14,488 | 23,647 | ||||||
| Sales and marketing | 24,742 | * | 24,742 | 21,413 | * | 21,413 | ||||||
| General and administrative | 12,519 | * | 12,519 | 9,502 | * | 9,502 | ||||||
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 | ||||||
| Add back: | ||||||||||||
| Items to reconcile net income or net loss to Adjusted EBITDA(3) | 8,776 | 5,569 | 14,345 | 8,127 | 5,813 | 13,940 | ||||||
| Adjusted EBITDA(3) | 12,138 | (10,360) | 1,778 | (4,111) | (5,106) | (9,217) | ||||||
| Items to reconcile to consolidated net loss: | ||||||||||||
| Share-based compensation expense(4) | (9,969) | (9,654) | ||||||||||
| Restructuring expense(5) | (643) | — | ||||||||||
| Impairment of long-lived assets(5) | (347) | — | ||||||||||
| Depreciation and amortization expense | (3,386) | (4,286) | ||||||||||
| Other unallocated items(1) | (7,448) | (6,673) | ||||||||||
| Net loss | $(20,015) | $(29,830) | ||||||||||
| *Non-significant segment expenses for Immune Medicine. | ||||||||||||
(1) Costs related to Digital Biotechnologies, Inc. are no longer included as Immune Medicine costs and have been reclassified to the “other unallocated items” total.
(2) For the Immune Medicine segment, includes all Immune Medicine operating expenses, other than research and development expenses.
(3) Adjusted EBITDA is a non-GAAP financial measure. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
(4) Represents share-based compensation expense related to various awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.
(5) Represents expenses recognized in conjunction with a restructuring that primarily impacted research and development activities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.